Research progress of EGFR related targeted therapy and pulmonary carcinoma

doi:10.3877/cma.j.issn.2095-8773.2017.01.11

Abstract

Abstract:

During the past several years, advances in the treatment of non-small cell lung cancer (NSCLC) have predominantly involved the development of therapies directed at molecular targets. Treatment based on histology and molecular characterization has become a guideline of care in the era of targeted therapy. Among numerous driver genes of NSCLC, epidermal growth factor receptor(EGFR) gene is one molecular target concerning with most researches, abundant evidences and thorough understandings. Epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI) has been widely used in the treatment of NSCLC haboring EGFR mutation. This review provides an overview of current EGFR gene related targeted therapies in NSCLC.

Key words: Non-small cell lung cancer, Pulmonary adenocarcinoma, Epidermal growth factor receptor, Molecular targeted therapy

Danyun Wang, Zhongmin Peng. Research progress of EGFR related targeted therapy and pulmonary carcinoma[J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2017, 04(01): 56-62.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxbwkdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-8773.2017.01.11

https://zhxbwkdzzz.cma-cmc.com.cn/EN/Y2017/V04/I01/56

References 40

1	Prenzel N, Fischer OM, Streit S, et al. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification[J]．Endocr Relat Cancer, 2001, 8(1):11-31.
2	Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network[J]．Nat Rev Mol Cell Biol, 2001, 2(2):127-137.
3	Sordella R, Bell DW, Haber DA, et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways[J]．Science，2004, 305(5687):1163-1167.
4	Yano M, Sasaki H, Kobayashi Y, et al. Epidermal growth factor receptor gene mutation and computed tomographic findings in peripheral pulmonary adenocarcinoma[J]．J Thorac Oncol, 2006, 1(5):413-416.
5	Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial[J]．Lancet Oncol, 2012, 13(3):239-246.
6	Goto K, Ichinose Y, Ohe Y, et al. Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase Ⅲ study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer[J]．J Thorac Oncol，2012, 7(1):115-121.
7	Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial[J]．Lancet Oncol, 2010, 11(2):121-128.
8	Pirker R, Pereira JR, von Pawel J, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study[J]．Lancet Oncol，2012, 13(1):33-42.
9	Tamura K, Fukuoka M. Molecular target-based cancer　 therapy: tyrosine kinase inhibitors[J]．Int J Clin Oncol, 2003, 8(4):207-211.
10	Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)[J]．Lancet, 2005, 366(9496):1527-1537.
11	Chang A, Parikh P, Thongprasert S, et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study[J]．J Thorac Oncol, 2006, 1(8):847-855.
12	Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer[J]．N Engl J Med，2005, 353(2):123-132.
13	Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase Ⅲ trial[J]．Lancet, 2008, 372(9652):1809-1818.
14	Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J]．N Engl J Med, 2009, 361(10):947-957.
15	Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR[J]．N Engl J Med, 2010, 362(25):2380-2388.
16	Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study[J]．Lancet Oncol，2011, 12(8):735-742.
17	Sequist LV, Yang JC, Yamamoto N, et al. Phase Ⅲ study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations[J]．J Clin Oncol, 2013, 31(27):3327-3334.
18	Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial[J]．Lancet Oncol，2014, 15(2):213-222.
19	Goss GD, O'Callaghan C, Lorimer I, et al. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study[J]．J Clin Oncol, 2013, 31(27):3320-3326.
20	Janjigian YY, Park BJ, Zakowski MF, et al. Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations[J]．J Thorac Oncol, 2011, 6(3):569-575.
21	Li N, Ou W, Ye X, et al. Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage ⅢA-N2 non-small cell lung cancer harbouring EGFR mutations: a randomized, phase Ⅱ study[J]．Ann Surg Oncol, 2014, 21(6):2091-2096.
22	Kelly K, Altorki NK, Eberhardt WE, et al. Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-ⅢA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase Ⅲ Trial[J]．J Clin Oncol, 2015, 33(34):4007-4014.
23	Lampaki S, Lazaridis G, Zarogoulidis K, et al. Defining the role of tyrosine kinase inhibitors in early stage non-small cell lung cancer[J]．J Cancer, 2015, 6(6):568-574.
24	Huang Q, Li J, Sun Y, et al. Efficacy of EGFR tyrosine kinase inhibitors in the adjuvant eatment for operable non-small cell lung cancer by a meta-analysis[J]．Chest, 2016, 149(6):1384-1392.
25	Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase Ⅲ trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer[J]．J Clin Oncol，2005, 23(25):5892-5899.
26	Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase Ⅲ study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial[J]．J Clin Oncol, 2007, 25(12):1545-1552.
27	Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase Ⅲ trial--INTACT 2[J]．J Clin Oncol，2004, 22(5):785-794.
28	Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase Ⅲ trial--INTACT 1[J]．J Clin Oncol，2004, 22(5):777-784.
29	Wu YL, Lee JS, Thongprasert S, et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial[J]．Lancet Oncol, 2013, 14(8):777-786.
30	Sugawara S, Oizumi S, Minato K, et al. Randomized phase Ⅱ study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902[J]．Ann Oncol, 2015, 26(5):888-894.
31	Cheng Y, Murakami H, Yang PC, et al. Randomized phase Ⅱ trial of Gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations[J]．J Clin Oncol, 2016，34(27):3258-3266.
32	Seto T, Kato T, Nishio M, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study[J]．Lancet Oncol, 2014, 15(11):1236-1244.
33	Janne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer[J]．N Engl J Med, 2015, 372(18):1689-1699.
34	Sequist LV, Soria JC, Goldman JW, et al. Rociletinib in EGFR-mutated non-small-cell lung cancer[J]．N Engl J Med, 2015, 372(18):1700-1709.
35	Wang W, Li Q, Takeuchi S, et al. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer[J]．Clin Cancer Res, 2012, 18(6):1663-1671.
36	Nakagawa T, Takeuchi S, Yamada T, et al. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer[J]．Mol Cancer Ther, 2012, 11(10):2149-2157.
37	Gou LY, Li AN, Yang JJ, et al. The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer[J]. Oncotarget, 2016，7(32):51311-51319.
38	Tan DS, Yom SS, Tsao MS, et al. The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016[J]．J Thorac Oncol, 2016, 11(7):946-963.
39	Hata A, Katakami N, Yoshioka H, et al. Prognostic impact of central nervous system metastases after acquired resistance to EGFR-TKI: poorer prognosis associated with T790M-negative status and leptomeningeal metastases[J]．Anticancer Res, 2015, 35(2):1025-1031.
40	Li YS, Jiang BY, Yang JJ, et al. Leptomeningeal metastases in patients with NSCLC with EGFR mutations[J]. J Thorac Oncol，2016，11(11):1962-1969.

[1]	Xiaowei Qi, Songqing Ye. Landscape of antibody-drug conjugates for breast cancer treatment [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(03): 129-135.
[2]	Changsheng Lin, Jun Zhan, Xue Xiao. Genetic testing and precision molecular targeted therapy in diagnosis and treatment of epithelial ovarian caner [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(05): 505-510.
[3]	Minrong Ma, Cong Li, Qin Zhou. Current research status of treatment of cervical cancer [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(05): 497-504.
[4]	Lu Wang, Yang Fan. Advances in endometrial cancer-related biomarker research [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(05): 511-516.
[5]	Lili Lou, Hanmin Liu. Current research status of susceptibility genes and epigenetics on childhood asthma [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(03): 249-255.
[6]	Kaiting Yu, Dong Wang, Hao Zhong, Meifang He, Jufang Wang. Expression and clinical significance of fibronectin 1 in breast cancer and its correlation with human epidermal growth factor receptor 2 [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(03): 203-210.
[7]	Changqing Cao, Xinyan Guo, Yuan Gao, Cun Zhang, Haili Tang, Dong Fan, Xiaojun Yang, Song Zhang, Huadong Zhao. Research progress on the involvement of tumor microenvironment in mediating trastuzumab resistance in HER2-positive breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 90-95.
[8]	Yujie Xu, Guodong Zhao. Advances and challenges in the treatment of advanced gastric cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(04): 451-455.
[9]	Chenglu Huang, Fei Liao, Xianping Liu, Zhiqiang Wang. Relationship between overexpression of serum exosomal has_circ_0060937 and metastasis and poor prognosis of NSCLC [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2023, 16(04): 490-494.
[10]	Yiran Li, Yuxiu Wang, Yan Zhu, Meng Wang, Ying Liu, Wenjin Yan, Xingxiang Xu, Lingfeng Min. Analysis of differential genes that affect the efficacy of Nivolumab and Pembrolizumab in the treatment of non-small cell lung cancer based on GEO database [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2023, 16(01): 20-25.
[11]	Kaimei Gan, Jian Huang. Research progress in the effect of lung cancer stem cells on EGFR-TKI drug resistance [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(01): 36-44.
[12]	Xiaoyong Wei. Discussion on the focus issues of conversion therapy for primary liver cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 602-607.
[13]	Yin Wu, Zhiqin Chen, Yong Gao, Ming Quan. Progress in diagnosis and treatment of Her-2 positive colorectal cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(05): 420-425.
[14]	Ruixue Yue, Lingxin Kong, Xin Hao, Jinqiang Yang, Meng Han, Guozhong Cui, Jianjun Wang, Zhisheng Zhang, Fanting Kong, Wei Zhang, Wenbo He, Xianqiao Li, Xinping Zhou, Donghong Xu, Chongzhu Hu. HER2 protein expression levels predict efficacy of neoadjuvant therapy in breast cancer: A real-world study [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(07): 765-770.
[15]	Junwei Cui, Yinhua Liu, Xiaoling Liu, Yibing Hu, Hui Hu. Efficacy and safety of trastuzumab and pertuzumab combined with chemotherapy in neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(11): 1062-1067.

Please choose a citation manager

Content to export